PAGoDA - Trk/Fms kinase inhibitor with gemcitabine in PDAC
Research type
Research Study
Full title
PAGoDA: A Phase Ib/IIa Trial Combining the Selective Dual Trk/CSF1R Kinase Inhibitor PLX7486 with Gemcitabine in Patients with Advanced Solid Tumours, or as First or Second-line Treatment for Locally Advanced or Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)
IRAS ID
213926
Contact name
Natalie Cook
Contact email
Sponsor organisation
NHS Greater Glasgow and Clyde Research and Development
Eudract number
2016-003267-19
ISRCTN Number
ISRCTN10978180
Duration of Study in the UK
2 years, 0 months, 0 days
Research summary
PLX-7486 is a drug that has been shown to suppress the growth of cancer cells in the laboratory, and may help to treat cancers. Gemcitabine is a chemotherapy drug that is widely used for the treatment of several cancers, including pancreatic cancer, lung cancer, ovarian cancer, breast cancer and bladder cancer. Both PLX-7486 and gemcitabine have been tested on their own. However this is the first time they have been tested together. This is being done because PLX-7486 in combination with gemcitabine has been shown to prolong survival in animal models compared with gemcitabine alone. The aim of this study is to see what dose of these two drugs can be given together safely and provide initial data on whether the combination may be more effective than gemcitabine alone in humans.
REC name
South Central - Oxford C Research Ethics Committee
REC reference
18/SC/0336
Date of REC Opinion
5 Jul 2018
REC opinion
Favourable Opinion